KALA BIO, Inc. — Director's Dealing 2017

Jul 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19

Reporting Person: Iwicki Mark T (Director, Chief Executive Officer, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-19	Stock Option (right to buy)	$15	A	78632	Acquired	2027-07-18	Common Stock (78632)	Direct

Footnotes

F1: This option was granted, effective on July 19, 2017 and vests over four years, with 2.0833% of the shares underlying the option vesting on August 31, 2017 and an additional 2.0833% of the shares vesting at the end of each successive one-month period thereafter.